Susan Weidner, Senior Vice President
Pharma and life sciences companies are exposed to a wide variety of market forces. The biggest challenge is to deliver efficient drugs, which is important not only from a patient health perspective but also from doctors’ reimbursement and their confidence in the drug perspectives. What adds to the stress is the constantly evolving market and the concomitant demand for new products that keeps pharma and life sciences firms on their toes. And the challenges grow exponentially in the area of specialty drugs for serious diseases where targeted therapy is a must. Amid these challenges, these companies tend to falter by resorting to working with familiar traditional clinical sites for patient recruitment, which often results in slow patient enrollment. For a winning value proposition, firms must have complete control and visibility over the end-to-end drug development process, from site selection to patient onboarding through clinical trial and validation.
IntrinsiQ Specialty Solutions (IntrinsiQ ), a division of AmerisourceBergen, helps pharma and life sciences companies and specialty physician practices nip the problems in the bud. Through its software solutions and analytics services, IntrinsiQ guides companies to make informed decisions at each stage of the drug development lifecycle, ranging from patient identification and recruitment, site selection, and so forth. “We bring deep, longitudinal patient data (including claims data) that facilitates advancements in clinical research, from clinical trials through real-world evidence,” says Susan Weidner, Senior Vice President of IntrinsiQ. “In addition, the data aids in bringing awareness and increasing adoption of the right strategies for physician education and marketing to drive product usage.”
It is crucial to maintain diversity in the patient population for favorable clinical research results. Especially in developing specialty drugs, biomarker profiling becomes the fundamental element of successful targeted therapy. As a relationship-centric company, IntrinsiQ works closely with its pharma and life sciences clients to broaden their outreach to patient and practice communities and galvanize as much diverse patient population as possible to participate in the research.
With its finger on the pulse of its clients’ needs, IntrinsiQ provides the right education for the clients’ teams to streamline their operations. “We take their clinical trial inclusion-exclusion criteria and align that against our data to educate and direct them to identify and onboard appropriate trial sites,” says Weidner.
In one instance, a drug manufacturer wanted to develop a targeted therapy for metastatic merkel cell carcinoma. But they were struggling to connect with the established academic centers, hospital outpatient departments, and large community-based practices; however, the desired sites were located in smaller rural areas.
We bring deep, longitudinal patient data (including claims data) that facilitates advancements in clinical research, from clinical trials through real-world evidence
IntrinsiQ turned the corner for this manufacturer with its ability to match the client’s project needs with the appropriate clinical trial sites within its network.
Actionable Insights for Stronger Headway
IntrinsiQ employs its analytical services to help pharma and life sciences clients analyze their product adoption and growth, both alone and in combination with other products across broad disease states. It also helps them understand appropriate contracting and education strategy to improve product adoption and physician behavior profiling for sales reps to deliver the message appropriately.
For specialty practitioners, IntrinsiQ provides strategic financial intelligence tools to solve their problems in the areas of productivity, payer contracting, and reimbursement. IntrinsiQ also guides them in understanding the key drivers for missing payouts and provides them with a referral network to set up an oncology care model. “Our reporting helps group purchasing organization members balance between GPO payer contracts and drug contracts,” says Weidner. Through this, IntrinsiQ maps out clients’ future roadmap in negotiating with payers and performing better against the existing contracts.
IntrinsiQ has built AdvanceIQ Network, a non-exclusive clinical research network focused on providing clinical access, from phase 1 through 4 clinical trials, patient registries for observational studies and real-world evidence studies. Specialty practices using IntrinsiQ’s solutions and services can become a member of AdvanceIQ Network for free. IntrinsiQ understands each participant’s inclusion-exclusion information to better evaluate their appropriateness for proposed studies across multiple specialties.
Client Engagement Strategy
“When we sit down with the sponsors to understand their study requirements, we evaluate the detailed medical records and shortlist patients with the right disease characteristics, attributes, comorbidities, and then engage the practices on the screening process to reach the patients on a timely basis,” says Weidner. IntrinsiQ also works with its sister company, Xcenda, to provide research support, from the beginning to the end of the product lifecycle, to clients conducting real-world evidence studies. The firm keeps track of the regulatory changes around training and documentation and enables practitioners and all the stakeholders in the project to update their processes accordingly.
A case in point, a small biotech firm had numerous innovative types of therapies for breast cancer but was struggling to find the right types of inclusion-exclusion criteria to structure the protocol appropriately. IntrinsiQ was called in to address the issue. IntrinsiQ analyzed massive structured and unstructured datasets to help them refine their protocol, inclusion, and exclusion criteria; identify appropriate research member sites; and start a swift enrollment process.
Marching forward, IntrinsiQ is looking forward to taking precision medicine from theory to practice. “We aim to strengthen the relationship with our life science sponsors for better care and greater business outcomes,” concludes Weidner.